Bayer to acquire UK-based biotech KaNDy Therapeutics Ltd. (for specialized target groups only)

Further expansion of Bayer’s drug development pipeline in Women’s Healthcare / Innovative non-hormonal oral compound NT-814 to alleviate menopausal symptoms / Development compound recently completed Phase IIb / Reinforces Bayer’s position in Women’s Healthcare / Upfront consideration of USD 425 million and additional potential consideration in the form of milestone payments
Read More

Leave a Reply

%d bloggers like this: